Zyla life sciences (EGLT)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13
Revenue
Net product sales

-

-

-

-

-

-

-

-

-

-

-

-

-

16,864

12,843

9,428

6,585

4,184

0

0

0

-

-

-

-

-

-

-

-

Related party revenue

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,920

0

0

0

-

-

-

-

Collaboration revenues

-

-

-

-

-

-

-

-

-

-

-

-

-

100

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Related party revenues

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

Revenue

82,783

79,527

68,383

0

0

-

0

-

-

26,136

24,473

22,533

19,728

16,964

30,204

27,179

24,688

22,830

4,278

2,938

2,469

1,920

0

0

0

-

-

-

-

Costs and Expenses
Cost of sales (excluding amortization of product rights)

31,536

40,553

38,800

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of product rights

13,988

12,823

9,852

0

0

-

0

-

-

2,082

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cost of sales (excluding amortization of product rights)

-

-

-

-

-

-

-

-

-

-

-

-

-

3,660

5,201

4,636

4,059

3,271

0

0

0

-

-

-

-

-

-

-

-

Amortization of product rights

-

-

-

-

-

-

-

-

-

-

-

-

-

2,006

1,996

1,999

2,081

1,958

0

0

0

-

-

-

-

-

-

-

-

General and administrative

26,430

22,321

22,382

0

0

-

0

-

-

34,065

35,679

36,780

33,163

30,670

33,096

30,661

27,611

26,474

20,289

18,601

17,313

15,715

13,478

10,903

7,503

5,095

0

0

0

Sales and marketing

37,377

32,536

31,514

0

0

-

0

-

-

35,532

35,838

34,008

30,948

27,892

24,609

23,919

20,923

16,289

11,496

5,580

2,508

946

0

0

0

-

-

-

-

Research and development

-

22

968

0

0

-

0

-

-

14,744

20,060

30,057

34,160

33,759

34,184

26,716

22,922

27,054

25,664

27,408

29,866

22,395

19,547

14,258

8,097

6,280

0

0

0

Restructuring and other charges

2,204

1,920

14,512

0

0

-

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of contingent consideration payable

8,783

4,983

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Impairment of goodwill

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total costs and expenses

125,165

115,158

121,723

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total costs and expenses

-

-

-

-

-

-

-

-

-

94,336

101,339

107,263

104,382

97,987

99,086

87,931

77,596

75,046

59,567

52,853

50,159

39,056

33,610

25,379

15,606

11,375

0

0

0

Loss from operations

-42,382

-35,631

-53,340

0

0

-

0

-

-

-68,200

-76,866

-84,730

-84,654

-81,023

-68,882

-60,752

-52,908

-52,216

-55,289

-49,915

-47,690

-37,136

-32,518

-24,633

-15,350

-11,375

0

0

0

Other (income) expense:
Change in fair value of warrant and derivative liability

-

-

-

-

-

-

0

-

-

2,546

1,514

3

46

644

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of derivative liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

Interest expense (income), net

-14,968

-13,353

-42,469

0

0

-

0

-

-

-17,666

-17,842

-16,768

-14,334

-12,109

-10,565

-9,344

-9,335

-7,477

-5,133

-2,748

-438

-7,079

-10,159

-11,531

0

-

0

0

-

Other gain, net

-

-

0

0

-

-

0

-

-

750

744

696

613

797

-52

0

0

-

-

0

-

-

-

-

-

-

-

-

-

Loss on foreign currency exchange

0

-

-

-

-

-

-

-

-

-

0

-

-

-2

5

0

-183

-82

-87

-39

102

3

-74

-244

-208

-190

0

0

0

Total other expense (income)

-11,627

-10,016

-37,094

0

0

-

0

-

-

-1,159

-15,585

-16,068

-13,679

-10,670

-8,669

-6,862

-7,781

-6,435

-4,354

-2,513

709

-6,031

-11,334

-14,585

-15,920

-8,810

0

0

0

Reorganization items

-

993

1,209

1,209

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

(Loss) income after reorganization charges and before provision (benefit) for income taxes

-

-

-

0

-

-

-

-

-

-

0

0

-

-91,693

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Loss before provision (benefit) for income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-43,852

-39,218

-31,270

-20,185

0

0

0

Provision (benefit) for income taxes

-

-

-

-

-

-

-

-

-

-

0

0

-

-1,061

-1,502

-1,143

-929

-718

-35

-1

38

47

0

0

0

-

-

-

0

Net (loss) income

-54,396

-46,640

-91,643

0

0

-

0

-

-56,341

-69,359

-92,170

-100,159

-97,457

-90,632

-76,049

-66,471

-59,760

-57,933

-59,608

-52,427

-47,019

-43,214

-43,960

-39,291

-31,327

-20,207

0

0

0

Per share information:
Net (loss) income per share of common stock—basic and diluted (in dollars per share)

-1.26

-0.43

-0.72

-1.37

-0.73

-

-0.93

-

-

0.47

-0.46

-1.04

-1.02

-0.87

-1.10

-0.97

-0.76

-0.08

-0.81

-1.03

-1.02

-0.27

-0.63

-0.73

-1.34

-7.13

-4.26

-2.86

-1.39

Weighted-average shares outstanding, basic and diluted (in shares)

14,443

14,334

14,333

14,333

14,333

-

55,192

-

-

43,563

41,149

25,542

24,766

24,618

24,565

24,468

24,406

24,463

21,530

16,506

16,451

16,495

16,206

15,887

9,638

1,292

1,292

1,292

1,292

Predecessor
Revenue

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cost of sales (excluding amortization of product rights)

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of product rights

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

General and administrative

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Sales and marketing

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Research and development

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total costs and expenses

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Loss from operations

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of warrant and derivative liability

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest expense, net

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other gain

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total other expense (income)

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

(Loss) income after reorganization charges and before provision (benefit) for income taxes

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net (loss) income

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net (loss) income per share of common stock, basic and diluted (in dollars per share)

-

-

-

-

-

-

-

-0.22

-0.26

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted-average shares outstanding, basic and diluted (in shares)

-

-

-

-

-

-

-

53,302

47,303

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-